Created at	Source	Raw Value	Validated value
March 14, 2021, 1 a.m.	irct	Vaccine efficacy of Shifa-pharmed inactivated SARS-COV-2 vaccine Neutralizing antibody (phase 2) Anti SARS-COV-2 antibody titer (IgG, IgM) (Geometric mean titer) (phase 2) Severe COVID-19 cases	Vaccine efficacy of Shifa-pharmed inactivated SARS-COV-2 vaccine Neutralizing antibody (phase 2) Anti SARS-COV-2 antibody titer (IgG, IgM) (Geometric mean titer) (phase 2) Severe COVID-19 cases